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ABSTRACT
Background: Regulatory T cells (Tregs) play an important role in sustaining the hepatitis B and C viruses 
(HBV and HCV) persistence and protecting the liver tissues from cytokine-associated detrimental effects through 
unclear mechanisms. This paper aims to review the frequency of Tregs during the course of HBV and HCV 
infection. 
Method: Electronic databases were searched to identify studies investigated the frequency of intrahepatic 
and peripheral Tregs of the patients infected with HBV and/ or HCV. 
Results: The majority of studies reported the increase of intrahepatic and peripheral Tregs in acute and 
chronic infection of HBV and HCV. The decrease of peripheral Tregs occurred in patients with chronic hepatitis 
%ZKRUHVSRQGWRLQWHUIHURQĮRUQXFOHRVWLGHDQDORJXHVWUHDWPHQWDVZHOODVWKRVHZLWKFKURQLFKHSDWLWLV&
who were treated with interferon, ribavirin or liver transplantation.
Conclusion: Infection with HBV and HCV appears to induce the production of Tregs in blood and hepatocytes 
whereas treatment may decrease Tregs levels. As the optimum balance between regulatory and effector T 
during HBV and HCV infection is crucial for preventing liver damage, further studies should be directed on 
the development of Tregs during HBV and HCV infection as well as their involvement in immunomodulatory 
strategies for combating HBV and HCV. 
Keywords: T-lymphocytes, regulatory, hepatitis B, hepatitis C
 ABSTRAK
Latar belakang: Regulatory T cells (Tregs) memainkan peranan penting dalam menjaga keberlangsungan 
infeksi virus hepatitis B dan C (HBV dan HCV) serta melindungi jaringan hati dari kerusakan yang diakibatkan 
oleh sitokin melalui mekanisme yang belum diketahui secara pasti. Artikel ini bertujuan untuk menelaah frekuensi 
Tregs selama perjalanan infeksi HBV dan HCV. 
Metode: 3HQXOLVPHQFDULDUWLNHOSHQHOLWLDQGLEDVLVGDWDHOHNWURQLN$UWLNHO\DQJGLLGHQWL¿NDVLDGDODKVWXGL
yang menginvestigasi frekuensi Treg di hati dan di sirkulasi darah dari pasien-pasien yang terinfeksi HBV dan/ 
atau HCV.
Hasil: Sebagian besar artikel melaporkan adanya peningkatan Tregs intrahepatik dan perifer pada infeksi 
HBV dan HCV, baik akut maupun kronik. Penurunan frekuensi Treg di perifer terjadi pada pasien dengan 
KHSDWLWLV%NURQLN\DQJEHUHVSRQWHUKDGDSSHQJREDWDQLQWHUIHURQĮDWDXDQDORJQXFOHRVWLGDGHPLNLDQSXOD
pada penderita hepatitis C yang diterapi dengan interferon, ribavirin atau transplantasi hati.
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Simpulan: Infeksi HBV dan HCV tampaknya menginduksi produksi Treg di darah dan sel-sel hati sedangkan 
pengobatan dapat menurunkan jumlah Treg. Keseimbangan yang optimal antara Treg dan T efektor selama infeksi 
HBV dan HCV penting untuk mencegah kerusakan hati. Oleh karena itu, diperlukan penelitian-penelitian lanjutan 
terkait perkembangan Treg selama infeksi HBV dan HCV serta keterlibatannya dalam strategi imunomodulasi 
untuk melawan HBV dan HCV.
Kata kunci: limfosit T, regulatory, hepatitis B, hepatitis C
INTRODUCTION
Hepatitis B and hepatitis C are important public 
health issues with increasing numbers of patients 
despite the immense efforts to control the transmission. 
The World Health Organization (WHO) estimated 
that in 2015, there were 257 million people have 
chronic HBV infection and 71 million cases of chronic 
HCV infection.1 Whilst antiviral and immunological 
treatments are available and on trials, none can 
eliminate the viruses and prevent the chronic sequel of 
HBV and HCV infection. Thus, it poses a substantial 
threat to the chronically infected patients as the 
infection cannot be totally cured, leading to terminal 
illness due to liver failure and carcinoma. The long-
term morbidity in hepatitis B and C cases are clearly 
associated with significant clinical and economic 
burden.2 
The rules of cellular and humoral immunity in 
hepatitis B and C have been widely studied but limited 
data exist regarding the role of regulatory T cells 
(Tregs) in the course of these illnesses. The majority 
of studies on hepatitis B immunity have frequently 
reported Natural Killer (NK), CD4+ cells, CD8+ cells, 
and antibodies to HBV. As for hepatitis C, previous 
reports have primarily focused on interferon response, 
antibodies HCV and cytotoxic T lymphocytes. Jung 
and Shin suggested that Tregs are involved in the 
disease chronicity by maintaining viral persistence and 
protecting the liver tissues from cytokine-associated 
detrimental effects.3
This paper presents a review of the available 
literature reporting studies that measure the frequency 
of Tregs in various states of HBV and HCV infection. 
METHOD
On 14 August 2017, literature were searched 
in PubMed, Scopus, Web of Science and Medline 
databases using the following terms: “regulatory 
T cell [Title/Abstract]” AND “hepatitis [Title/
Abstract]” AND “infection”. The results were reviewed 
systematically according to PRISMA guidance.4 
Inclusion criteria included journal articles published 
in English that described Tregs in HBV and HCV 
research. Review articles were excluded as well as 
case reports and studies that focused on children, 
PDOLJQDQF\LQÀDPPDWRU\RUDXWRLPPXQHGLVHDVHVDQG
those including other pathogens such as co-infection 
with human immunodeficiency virus (HIV). The 
DUWLFOHV LGHQWL¿HGZHUH UHYLHZHGV\VWHPDWLFDOO\DQG
references of the included papers were also examined.
RESULTS
7KH LQLWLDO VHDUFK LGHQWL¿HG  DUWLFOHV$IWHU
removing duplicate articles, 129 articles remained, of 
which 35 were removed after reading their titles and/or 
abstracts. The entire texts of the 94 remaining articles 
were reviewed, of which 37 passed all exclusion 
criteria and met all inclusion criteria. After evaluating 
the references, listed in 37 articles above, 18 articles 
were added to the review resulting in the total of 55 
articles being analysed. (Figure 1)
Table 1 summarizes the 55 studies evaluating Tregs 
levels at different stages of HBV or HCV infection. 
The majority of studies involved chronically infected 
patients. Only two studies reported Tregs level in acute 
hepatitis B (AHB) and the other two studied acute 
hepatitis C (AHC).5,6,31,32 Five studies reported Tregs 
level in patients with HBV-related acute-on-chronic 
liver failure (ACLF).9,10,21-23
During the acute stage of HBV infection, the 
frequency of peripheral Tregs remains normal whilst 
HCV caused an immediate increase of Tregs level in 
circulation. Most patients with chronic HBV and HCV 
infection had an increase of Tregs level in their blood 
circulation and liver. The treatment of chronic hepatitis 
B could reduce Tregs frequency but in patients with 
chronic hepatitis C, the results were not consistent.
DISCUSSION 
Overal, there are 20 longitudinal studies and 34 
cross-sectional studies. One study performed both 
longitudinal and cross-sectional approaches.47 For the 
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Additional records 
identified from reference 
list (n = 18)
Records identified through 
database searching  
(n = 224) 
Titles and abstracts reviewed 
(n = 129) 
Full-text articles assessed 
(n = 94)  
Studies included in analysis 
(n = 37) 
Total article included in the 
final analysis (n = 55) 
Duplicates removed  
(n = 95) 
Excluded (n =35) 
17 not relevant (i.e., studies on liver transplant, 
antiviral medication, infection other than HBV/HCV) 
12 review articles, 1 case report  
5 met exclusion criteria: [1 study on children, 3 
study on inflammatory or autoimmune diseases  
(2 vasculitis, 1 IHD), 1 study on malignancy (NHL)] 
Excluded (n = 57) 
49 not relevant to the topic being  
reviewed 
8 met exclusion criteria:  
 4 studies on co-infection 
4 studies on malignancy
+%9KHSDWLWLV%YLUXV+&9KHSDWLWLVFYLUXV1+/QRQ+RGJNLQO\PSKRPD,+'LQÀDPPDWRU\KHDUWGLVHDVH
)LJXUH7KHZRUNÀRZRIV\VWHPDWLFVHDUFKDQGDQDO\VLV
longitudinal studies, the follow up time is considered 
VXI¿FLHQW$OOWKHVWXGLHVFOHDUO\GH¿QHGWKHFULWHULDIRU
inclusion. Study subjects and setting were described in 
detail and the measurements were performed according 
to the standards methods. The accurate measurements 
together with the appropriate use of statistical analysis 
resulting in valid and reliable results of the reviewed 
studies. Unfortunately, confounding factors and 
strategies to deal with them were not elaborated in 
detail, perhaps due to the complexity of immunological 
responses in HBV and HBC infection as well as the 
extent of biological variations amongst study subjects. 
Chronic infection with HBV and HCV may cause 
immune-mediated liver injury that leads to liver 
cirrhosis, hepatocellular carcinoma, and liver failure. 
Until now, not all of chronic hepatitis B and C patients 
can be cured. Currently available treatments may slow 
down the progressivity of the illness, decrease the viral 
load and ease the symptoms but the viral clearance may 
not be completely achieved. The available direct-acting 
antiviral drugs are well tolerated and cause sustained 
virological response in most patients with chronic 
hepatitis C. However, treatment failure may happen in 
some patients due to the lack of adherence and drug-
to-drug interactions. If the infection persist, a constant 
exposure to the virus antigens will provoke the immune 
response and sooner or later, liver transplantation is 
the only solution for patients with irreversible liver 
damage. The limited liver donors and the continuing 
increase of demands cause more patients left untreated. 
Therefore, understanding immunological aspects of 
+%9DQG+&9LQIHFWLRQLVLPSRUWDQWWR¿QGDZD\WR
improve patient care.
The main immunological response to HBV and 
HCV infection is performed by a subset of white blood 
cells called T lymphocytes (T cells). An adequate 
response of T cells is necessary for spontaneous 
resolution during acute infection and for preventing 
permanent chronic infection. Even though T cells 
frequency correlates inversely with the viral load, T 
cells may contribute to liver damage through unknown 
mechanisms.60 It has been argued that liver damage in 
FKURQLFKHSDWLWLVSDWLHQWVZDVGXHWRSURLQÀDPPDWRU\
F\WRNLQHVSURGXFHGE\QRQVSHFL¿F7FHOOVGXULQJWKH
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viral clearance from liver cells. Therefore, it can be 
assumed that the key to cure chronic hepatitis B and 
C is by restoring an effective T cells response.
The roles of Tregs in chronicity of HBV infection 
KDYHEHHQFRQ¿UPHG,QFUHDVHG7UHJVFRUUHODWHZLWK
poor short-term outcomes in HBV-related acute-on-
chronic liver failure patients.9 While there is clinical 
evidence of a relevant role for Tregs in chronic HCV-
infected patients, based on their increased number and 
function; mechanisms underlying such phenomena are 
still poorly understood.61 This present review shows 
that the frequency of Tregs is associated with the 
chronicity of HBV and HCV infection. The increase 
of intrahepatic Tregs during chronic infection may 
be directed to protecting liver tissue from immune-
mediated injury whereas the decrease of Tregs 
IUHTXHQF\PD\EHLQÀXHQFHGE\WKHWUHDWPHQWJLYHQ
i.e. the type and duration of treatment. Thus, analyzing 
Tregs frequency during the course of hepatitis B and 
C may give a valuable information to clinicians with 
regards to disease chronicity, the severity of the ilness, 
and response to treatment. 
CONCLUSION
The role of Tregs for suppression of immune 
responses during HBV and HCV infection is vital 
to prevent immune-mediated liver injury. On the 
other hand, the suppression of immune responses in 
¿JKWLQJYLUDOUHSOLFDWLRQSRVHVDGHWULPHQWDOHIIHFWDV
this causes persistent infection. These contrary effects 
RI7UHJVPD\ LQÀXHQFH WKH FOLQLFDO FRXUVH RI+%9
and HCV-infected patients. This review shows that 
infection with HBV and HCV promotes the increase 
of Tregs in patients’ blood and hepatocytes whereas the 
treatments may decrease Tregs levels. Further studies 
are needed to examine the dynamics of Tregs during 
the course of infection and its relation with clinical 
outcomes. Such studies are important to understand 
the immunologic properties of Tregs and may be 
developed as a novel strategy to combat hepatitis B 
and C. 
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